PMCC PMCC

Search tips
Search criteria

Advanced
Results 1-25 (59)
 

Clipboard (0)
None

Select a Filter Below

Journals
Year of Publication
Document Types
1.  Diagnosis and Management of Heparin-Induced Thrombocytopenia 
doi:10.1016/j.hoc.2013.02.001
PMCID: PMC3668315  PMID: 23714311
platelet factor 4; PF4; heparin; PF4/H complexes; HIT
2.  Immune Thrombocytopenia 
Immune thrombocytopenia (ITP) is a common hematologic disorder characterized by isolated thrombocytopenia. ITP presents as a primary form characterized by isolated thrombocytopenia (platelet count < 100 × 109/L) in the absence of other causes or disorders that may be associated with thrombocytopenia, or a secondary form in which immune thrombocytopenia develops in association with another disorder that is usually immune or infectious. ITP may affect individuals of all ages, with peaks during childhood and in the elderly, in whom the age specific incidence of ITP is greatest. Bleeding is the most common clinical manifestation of ITP, with the risk of bleeding and related morbidity increased in elderly patients. The pathogenesis of ITP is complex, involving alterations in humoral and cellular immunity. Thrombocytopenia is caused by antibodies that react with glycoproteins expressed on platelets and megakaryocytes (glycoprotein IIb/IIIa, Ib/IX and others), causing shortened survival of circulating platelets and impairing platelet production. Diminished numbers and function of regulatory T cells, as well as the effects of cytotoxic T cells also contribute to the pathogenesis of ITP. Corticosteroids remain the most common first line therapy for ITP, occasionally in conjunction with intravenous immunoglobulin (IVIg) and anti-Rh(D). However, these agents do not lead to durable remissions in the majority of adults with ITP, and considerable heterogeneity exists in the use of second line approaches, which may include splenectomy, Rituximab, or thrombopoietin receptor agonists (TRAs). This review summarizes the classification and diagnosis of primary and secondary ITP, as well as the pathogenesis and options for treatment. Remarkable advances in the understanding and management of ITP have been achieved over the last decade, though many questions remain.
doi:10.1016/j.hoc.2013.03.001
PMCID: PMC3672858  PMID: 23714309
immune; thrombocytopenia; ITP; platelets; thrombopoietin; splenectomy
3.  Genetic Dissection of Platelet Function in Health and Disease Using Systems Biology 
doi:10.1016/j.hoc.2013.03.002
PMCID: PMC3767180  PMID: 23714307
Gene profiling; Thrombosis; Hemostasis; Megakaryocytopoiesis; Proteomics
4.  Harnessing the Platelet Signaling Network to Produce an Optimal Hemostatic Response 
doi:10.1016/j.hoc.2013.02.002
PMCID: PMC3787971  PMID: 23714305
Platelets; Hemostasis; Vascular injury; Signal transduction; Networks; G protein–coupled receptors; G proteins; Integrins
5.  Curing All Patients with Acute Promyelocytic Leukemia: Are We There Yet? 
Acute promyelocytic leukemia (APL) is a distinct morphologic variant of acute myeloid leukemia (AML), accounting for approximately 10% to 15% of the adult cases of AML diagnosed in the United States annually.1 The leukemia cells are usually easy to distinguish morphologically from others2 and are characterized by a specific reciprocal translocation t(15;17),3 which fuses the PML (promyelocyte) gene from chromosome 15 to the RAR-α (retinoic acid receptor-α) gene of chromosome 17.4 Consistently found in all cases of t(15;17) APL, the resulting PML-RARα fusion gene on der(15) encodes a chimeric transcript of the 2 DNA-binding domains that shows altered transcriptional regulatory properties, eventually leading to the block of retinoic-acid– induced myeloid differentiation.4
doi:10.1016/j.hoc.2011.10.002
PMCID: PMC4021483  PMID: 22093584
Acute promyelocytic leukemia; All-trans retinoic acid; Arsenic trioxide; Targeted therapies; Cure
6.  CAR Therapy for CLL: What are the Challenges? 
Synopsis
Numerous targeted therapies are being developed for patients with CLL. CAR-modified T cells targeting CD19 expressed by normal and malignant B cells is a unique therapy and recent results from four different trials highlight the dramatic potential of this therapy for patients with relapsed CLL. Since adoptive transfer of CAR-modified T cells is a novel approach to cancer therapy there are issues for the medical oncologist to consider when evaluating current and future clinical trials for patients with CLL. Herein, we review the impact of CAR design, T cell production, T cell dose, conditioning regimens, and tumor burden at the time of CAR-modified T cell infusion on the efficacy of this therapy.
doi:10.1016/j.hoc.2012.12.004
PMCID: PMC3615434  PMID: 23561477
Chimeric Antigen Receptor; Chronic Lymphocytic Leukemia; CD19; Adoptive cell therapy; Cell engineering
7.  Phosphoinositide 3-Kinase Inhibition in Chronic Lymphocytic Leukemia 
Phosphoinositide 3’-kinase (PI3K) is a key node in the B cell receptor (BCR) pathway, which plays a crucial role in the trafficking, survival, and proliferation of chronic lymphocytic leukemia (CLL) cells. We review the biology of the PI3K with a focus on its relationship to the CLL microenvironment. We then discuss the biologic rationale underlying the development of PI3K inhibitors in CLL. Delta-isoform specific PI3K inhibitors such as GS1101 (formerly CAL-101) are highly selective for CLL cells and have progressed furthest in their clinical development. Though less specific, pan-PI3K inhibitors and dual PI3K/mTOR inhibitors have the potential to overcome possible resistance mechanisms to isoform-specific inhibition. In early phase clinical trials, PI3K inhibitors appear to be highly active in relapsed refractory CLL, including in high-risk disease such as del(17p). Like other BCR pathway antagonists, they typically induce early transient lymphocytosis with associated nodal response. We examine potential biomarkers for clinical response to PI3K inhibitors such as ZAP-70, IGHV status, and CCL3. We also explore where PI3K inhibition may fit in the evolving landscape of CLL therapy.
doi:10.1016/j.hoc.2012.12.002
PMCID: PMC3615463  PMID: 23561476
Lymphoid Leukemia; Signaling Therapies
8.  Genomic Approaches to Chronic Lymphocytic Leukemia 
Synopsis
This article discusses recent advances in genomic approaches used to understand chronic lymphocytic leukemia (CLL). We describe tools for analyzing DNA sequence level alterations, summarize data obtained from these various platforms, and discuss the clinical relevance of these findings.
doi:10.1016/j.hoc.2013.01.001
PMCID: PMC3615477  PMID: 23561468
CLL; Genomics; CGH; SNP Arrays; Linkage Mapping; GWAS; Whole-exome sequencing; Whole-genome sequencing
9.  Biology of Chronic Lymphocytic Leukemia in Different Microenvironments: Clinical and Therapeutic Implications 
doi:10.1016/j.hoc.2013.01.002
PMCID: PMC3660068  PMID: 23561469
Chronic lymphocytic leukemia; Microenvironment; B-cell receptor signaling; Targeted therapy
10.  Chronic Granulomatous Disease 
doi:10.1016/j.hoc.2012.11.002
PMCID: PMC3558921  PMID: 23351990
chronic granulomatous disease; gene defects; NADPH oxidase; immune defect; neutropenia
11.  Animal Models of Human Granulocyte Diseases 
In vivo animal models have proven very useful to understand basic biological pathways of the immune system, a prerequisite for the development of innovate therapies. This manuscript addresses currently available models for defined human monogenetic defects of neutrophil granulocytes, including murine, zebrafish and larger mammalian species. Strengths and weaknesses of each system are summarized, and clinical investigators may thus be inspired to develop further lines of research to improve diagnosis and therapy by use of the appropriate animal model system.
doi:10.1016/j.hoc.2012.10.005
PMCID: PMC3558998  PMID: 23351993
Chronic granulomatous disease; leukocyte adhesion deficiency; severe congenital neutropenia; neutrophils; mouse models; zebrafish models
12.  ELANE Mutations in Cyclic and Severe Congenital Neutropenia—Genetics and Pathophysiology 
There are two main forms of hereditary neutropenia: cyclic and severe congenital neutropenia (SCN). Cyclic neutropenia is an autosomal dominant disorder in which neutrophil counts fluctuate between nearly normal levels and close to zero with 21-day periodicity. In contrast, SCN, also known as Kostmann syndrome, consists of chronic and profound neutropenia, with a characteristic promyelocytic maturation arrest in the bone marrow. Unlike cyclic neutropenia, SCN displays frequent acquisition of somatic mutations in the gene, CSF3R, encoding the Granulocyte Colony-Stimulating Factor Receptor (G-CSFR), and a strong predisposition to developing myelodysplasia (MDS) and/or acute myeloid leukemia (AML). Cyclic neutropenia is caused by heterozygous mutations in the gene, ELANE (formerly known as ELA2), encoding the neutrophil granule serine protease, neutrophil elastase. SCN is genetically heterogeneous, but it is most frequently associated with ELANE mutations. While some of the different missense mutations in ELANE exhibit phenotype-genotype correlation, the same mutations are sometimes found in patients with either form of inherited neutropenia. The mutations lead to production of a mutant polypeptide, but no common biochemical abnormality, including effects on proteolysis, has been identified. Two non-mutually exclusive theories have been advanced to explain how the mutations might produce neutropenia. The mislocalization hypothesis states that mutations within neutrophil elastase or involving other proteins responsible for its intracellular trafficking cause neutrophil elastase to accumulate in inappropriate subcellular compartments. The misfolding hypothesis proposes that mutations prevent the protein from properly folding, thereby inducing the stress response pathway within the endoplasmic reticulum (ER). We discuss how the mutations themselves provide clues into pathogenesis, describe supporting and contradictory observations for both theories, and highlight outstanding questions relating to pathophysiology of neutropenia.
doi:10.1016/j.hoc.2012.10.004
PMCID: PMC3559001  PMID: 23351986
Cyclic neutropenia; Severe congenital neutropenia; ELANE; Neutrophil elastase; Granulocyte-colony stimulating factor (G-CSF)
13.  The History and Future of Chemotherapy for Melanoma 
Melanoma is considered a chemotherapy-resistant tumor, but in fact several chemotherapeutic agents show single-agent activity at the level of 10% to 15%, similar to the efficacy of the chemotherapeutic armamentarium used against other tumor types. Several combination chemotherapy regimens have been tested, but no survival benefit has been demonstrated. Few of these trials have been compared with standard dacarbazine (DTIC) in an adequately powered randomized trial, and even the largest of these trials were only powered to detect unrealistically large improvements in overall survival. In this article, the authors review past chemotherapy trials and the current state of chemotherapy for melanoma. Looking to the future, the authors are encouraged by recent observations that the addition of sorafenib to DTIC (or temozolomide) can increase response rates and survival. The authors suggest that this could form the core on which additional active chemotherapeutic drugs could be added with the hope of developing a regimen that improves overall survival. This paradigm of stepwise addition of active chemotherapeutic drugs has been successful in the development of chemotherapy regimens that improve survival in other solid tumor systems. In colon carcinoma, for example, the current regimens were built on fluorouracil (5FU)/leucovorin, which has similar activity to DTIC in melanoma. This could serve as a model for studies on melanoma.
doi:10.1016/j.hoc.2009.03.006
PMCID: PMC3904102  PMID: 19464604
Dacarbazine; Temozolomide; Cisplatin; Sorafenib; Combination chemotherapy
14.  Breast Cancer Survivorship Issues 
doi:10.1016/j.hoc.2013.05.005
PMCID: PMC3903408  PMID: 23915746
Vasomotor symptoms; Sexual dysfunction; Infertility; Osteoporosis; Musculoskeletal pain; Cognitive changes; Neuropathy; Treatment-related cancers
15.  Immunosuppression for Myelodysplastic Syndrome: How Bench to Bedside to Bench Research Led to Success 
doi:10.1016/j.hoc.2010.02.009
PMCID: PMC3793398  PMID: 20359629
Immunosuppression; Myelodysplastic syndrome; Tumor necrosis factor; IFNγ
16.  Role of TET2 and ASXL1 mutations in the pathogenesis of myeloproliferative neoplasms 
Synopsis
Since the discovery of activating mutations in JAK2 in patients with myeloproliferative neoplasms (MPNs) in 2005, gene discovery efforts have identified additional disease alleles which can predate or occur subsequent to acquisition of JAK2/MPL mutations. In 2009, single nucleotide polymorphism (SNP) arrays and comparative genomic hybridization array (aCGH) based profiling led to the identification of somatic copy-number loss and mutations in the genes TET2 and ASXL1 in MPN patients. Biochemical and biological characterization of the TET and ASXL family of proteins have provided valuable insights into new modes of epigenetic regulation of gene transcription. Mutations in TET2 and ASXL1 are also important biomarkers for disease outcome amongst patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Despite these important insights, the relevance of these mutations to outcome and to therapeutic response in MPN patients is not yet clear. Genetic analysis of MPN patient cohorts with adequate sample size and clear clinical annotation are needed to understand the importance of these mutations on MPN phenotype, risk of transformation to leukemia, response to therapy, and influence on overall survival.
doi:10.1016/j.hoc.2012.07.006
PMCID: PMC3459179  PMID: 23009937
ASXL1; TET2; Myelofibrosis; Myeloproliferative Neoplasms; JAK2
17.  Myeloproliferative Neoplasm Animal Models 
Synopsis
Myeloproliferative neoplasm (MPN) animal models accurately re-capitulate human disease in mice and have been an important tool for the study of MPN biology and therapy. Transplantation of BCR-ABL transduced bone marrow cells into irradiated syngeneic mice established the field of MPN animal modeling and the retroviral bone marrow transplantation (BMT) assay has been used extensively since. Genetically engineered MPN animal models have enabled detailed characterization of the effects of specific MPN associated genetic abnormalities on the hematopoietic stem and progenitor cell (HSPC) compartment and xenograft models have allowed the study of primary human MPN-propagating cells in vivo. All models have facilitated the pre-clinical development of MPN therapies. JAK2V617F, the most common molecular abnormality in BCR-ABL negative MPN, has been extensively studied using retroviral, transgenic, knock-in and xenograft models. MPN animal models have also been used to investigate additional genetic lesions found in human MPN and to evaluate the bone marrow microenvironment in these diseases. Finally, several genetic lesions, although not common, somatically mutated drivers of MPN in humans induce a MPN phenotype in mice. Future uses for MPN animal models will include modeling compound genetic lesions in MPN and studying myelofibrotic transformation.
doi:10.1016/j.hoc.2012.07.007
PMCID: PMC3459181  PMID: 23009938
Myeloproliferative neoplasms; preclinical murine models; BCR-ABL; JAK2V617F; hematopoietic stem cells; bone marrow microenvironment; myelofibrosis; oncogenes
18.  The Antifolates 
doi:10.1016/j.hoc.2012.02.002
PMCID: PMC3777421  PMID: 22520983
Methotrexate; pralatrexate; pemetrexed; antifolates; reduced folate carrier (RFC); proton-coupled folate transporter (PCFT); folate receptors; folate receptor-mediated endocytosis
19.  Targeting Angiogenesis in Gynecologic Cancers 
doi:10.1016/j.hoc.2012.01.009
PMCID: PMC3334841  PMID: 22520979
20.  Targeting the Insulin Growth Factor Receptor 1 
Synopsis
The IGF axis is a tightly controlled endocrine system that regulates cell growth and development, known to have an important function in cancer biology. IGF1 and IGF2 can promote cancer growth in a GH-independent manner both through paracrine and autocrine secretion and can also confer resistance to chemotherapy and radiation. Many alterations of this system have been found in neoplasias, including increased expression of ligands and receptors, loss of heterozigosity of the IGF2 locus and increased IGF1R gene copy number. The IGF1 network is an attractive candidate for targeted therapy, including receptor blockade with monoclonal antibodies and small molecule inhibitors of receptor downstream signaling. This article reviews the role of the IGF axis in the initiation and progression of cancer, and describes the recent advances in IGF inhibition as a therapeutic tool.
doi:10.1016/j.hoc.2012.01.004
PMCID: PMC3334849  PMID: 22520978
IGF1R; IGF1; IGF2; insulin; kinase; cancer
21.  Tyrosine Kinase Inhibitors in Lung Cancer 
SYNOPSIS
‘Driver mutations’ are essential for carcinogenesis as well as tumor progression as they confer a selective growth advantage to cancer cells. Identification of driver mutations in growth related protein kinases, especially tyrosine kinases have led to clinical development of an array of tyrosine kinase inhibitors in various malignancies, including lung cancer. Inhibition of epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinases have proven to be of meaningful clinical benefit, while inhibition of several other tyrosine kinases have been of limited clinical benefit, thus far. An improved understanding of tyrosine kinase biology has also led to faster drug development, identification of resistance mechanisms and ways to overcome resistance. In this review, we discuss the clinical data supporting the use and practical aspects of management of patients on epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors.
doi:10.1016/j.hoc.2012.02.001
PMCID: PMC3334853  PMID: 22520981
Non-small cell lung cancer; tyrosine kinase inhibitor; epidermal growth factor receptor; ALK-translocation; Vascular endothelial growth factor
22.  Therapeutic antibodies against cancer 
Antibody-based therapeutics against cancer are highly successful in clinic and currently enjoy unprecedented recognition of their potential; 13 monoclonal antibodies (mAbs) have been approved for clinical use in the European Union and in the United States (one, mylotarg, was withdrawn from market in 2010). Three of the mAbs (bevacizumab, rituximab, trastuzumab) are in the top six selling protein therapeutics with sales in 2010 of more than $5 bln each. Hundreds of mAbs including bispecific mAbs and multispecific fusion proteins, mAbs conjugated with small molecule drugs and mAbs with optimized pharmacokinetics are in clinical trials. However, challenges remain and it appears that deeper understanding of mechanisms is needed to overcome major problems including resistance to therapy, access to targets, complexity of biological systems and individual variations.
doi:10.1016/j.hoc.2012.02.013
PMCID: PMC3334873  PMID: 22520975
therapeutics; antibodies; cancer; immunogenicity; safety; efficacy
23.  Poly(Adenosine Diphosphate–Ribose) Polymerase Inhibitors in Cancer Treatment 
Recently, the development of poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitors has brought a major breakthrough in the treatment of germline breast cancer susceptibility gene (BRCA)-mutant cancers.1-4 These agents target a DNA repair pathway via a novel mechanism of action. A better understanding of DNA damage repair mechanisms can extend the therapeutic application of this novel drug class to a wide range of sporadic cancers. Early clinical success has accelerated the development of various PARP inhibitors that are being explored in many cancers with single agents or in combination with chemotherapy or radiotherapy. In this article, the authors review DNA repair mechanisms and the role of PARP as a therapeutic target and summarize available PARP inhibitors, their clinical trials, biomarkers of PARP inhibitor sensitivity, and resistance mechanisms.
doi:10.1016/j.hoc.2012.02.012
PMCID: PMC3600582  PMID: 22520984
Poly(ADP-ribose) polymerase; Inhibitor; Synthetic lethality; BRCA
24.  Does My Patient with a Serum Monoclonal Spike have Multiple Myeloma? 
A monoclonal spike (M spike or paraprotein) on serum protein electrophoresis (SPEP) is a frequent finding in the general population and typically is pathognomonic of an asymptomatic, premalignant condition called monoclonal gammopathy of undetermined significance (MGUS). MGUS occurs in around 3% of people older than 50 and is associated with a lifelong, low, yet non negligible, risk of progression to multiple myeloma (MM) or a related plasma cell dyscrasia. It is generally an incidental diagnosis during the evaluation of patients complaining of various symptoms such as fatigue, forgetfulness, or neuropathy. While in most outpatient encounters the paraprotein is non pathogenic and cannot explain the presenting symptoms, both patients and physicians are faced with the medical, psychological and economic consequences of a premalignant diagnosis that is non curable, and the obligation (or lack thereof) for follow up. Lifelong annual medical evaluation and blood testing are currently recommended as a mean to early diagnose progression into asymptomatic (smoldering) or active MM. Recently the foundation of these recommendations have been challenged considering the low rate of progression and potential harm related to over-testing.
As MM remains an incurable disease, a timely diagnosis is crucial to establish an adequate plan of care and potentially prevent significant comorbidities such as pathologic fractures or kidney failure.
In this article we will discuss the criteria for diagnosis of MGUS, smoldering MM (SMM) and symptomatic MM; the risk factors for progression from MGUS and SMM to MM; the current recommendations for follow up of MGUS patients and diagnostic evaluation of suspected MM transformation.
doi:10.1016/j.hoc.2012.02.009
PMCID: PMC3319353  PMID: 22463833
25.  Cytogenetics and Molecular Genetics of Acute Lymphoblastic Leukemia 
doi:10.1016/j.hoc.2009.07.001
PMCID: PMC3607311  PMID: 19825449
Acute lymphoblastic leukemia; gene mutations, chromosome aberrations; human; prognosis

Results 1-25 (59)